Intensive chemotherapy will induce a complete morphologic remission (CR) in many persons with acute myeloid leukemia (AML). Even with continued treatment, however, relapse is common [1, 2] . Many pretreatment factors, most notably cytogenetic and molecular profiles, are associated with disease recurrence and shorter survival and allow outcome prediction, albeit with limited accuracy, at the individual patient level [3] [4] [5] . It is increasingly recognized that post-treatment information provides valuable insight into which remissions are of higher quality. One important characteristic of more durable remissions is the lack of measurable residual disease (MRD) [6] . On the other hand, whether it matters that a remission is obtained early, i.e., with the first cycle of chemotherapy, has remained controversial. Data from historic and contemporary trials with double induction chemotherapies showed patients who achieved a CR with the first induction cycle were less likely to relapse than those requiring two courses of therapy to enter CR [7, 8] . Contrasting these findings, an analysis of six ECOG (now ECOG-ACRIN) trials conducted between 1983 and 1993 indicated patients who achieved a CR after one or two cycles of induction chemotherapy had similar prognoses [9] . The relationship between timing of remission achievement and outcome has not been examined in contemporary cohorts of adults treated with 7+3. Here, we used data from participants of five SWOG trials between 1983 and 2015 and studied the association between prognosis and need for 7+3 reinduction therapy and how it has changed over time.
We analyzed 1247 patients randomized to 7+3 in treatment arms of five National Cancer Institute (NCI)/National Clinical Trials Network (NCTN) trials conducted by SWOG. We analyzed patients aged 65 and younger: S8600 [10] (n = 530), S9031 [11] (n = 98), S9333 [12] (n = 57), S0106 [13] (n = 301), and S1203 [14] CR was defined conventionally (<5% marrow blasts by morphology, absolute neutrophil count [ANC] ≥1000/µL, platelets ≥100,000/µL) [2] . Overall, survival (OS) was measured from the date of study registration/randomization to date of death due to any cause; patients last known to be alive were censored at the date of last contact. Relapsefree survival (RFS) was measured from the date of CR to the first of relapse from CR or death due to any cause; patients last known to be alive in CR were censored at the date of last contact. OS and RFS were estimated using the Kaplan-Meier method. Multivariable Cox regression models included covariates (modeled quantitatively unless otherwise specified): age at study registration, gender, cytogenetic risk, pre-study white blood cell counts (WBC), pre-study platelets, pre-study marrow blasts, type of AML (secondary vs. de novo), indicator of receiving reinduction and study/protocol. We analyzed study/protocol separately and also grouped the studies by 20-year period (S8600/ S9031/S9333 representing 1980s and 1990s vs. S0106/ S1203 representing 2000s and 2010s). The earlier of these groups (S8600/S9031/S9333) corresponds to the period of time covered in the analyses previously reported by ECOG-ACRIN [9] . NPM1 and FLT3 mutation data were available for participants of S0106 and S1203 and separate regression models in restricted to these two trials were fit that included these molecular data. To control for the fact that patients needed to live long enough to receive reinduction, we performed landmark analyses among the patients who were alive at day 45. However, to allow more direct comparison with the data previously reported by ECOG-ACRIN, which were not based on landmark analyses [9] , we also performed analyses among all patients. All analyses were performed with R (http://www.rproject.org). Table 1 summarizes the characteristics of the 1247 patients included in our analysis, group by decade of treatment (S8600 vs. S9031/S9333 vs. S0106 vs. S1203). Consistent with the differences in eligibility criteria noted above, patients enrolled in S9031/S9333 were older than those on the other studies. The proportion of patients with performance status 2 and higher decreased over time. In contrast, CR rates were higher in the studies conducted more recently compared to the earlier ones. In parallel with improved CR rates, OS and RFS were higher in S0106 and S1203 compared to S8600 and S9031/S9333 (Fig. 1a, b) .
We then built multivariable models to examine the relationship between CR achievement with the second cycle of 7+3 and OS as well as RFS in the older cohort of studies (S8600, S9031, and S9333) as well as the newer cohort of studies (S0106 and S1203) separately. After adjustment for age, gender, performance status, cytogenetic risk, WBC, platelet count, percentage of blasts in the bone marrow, and type of AML, CR achievement only upon reinduction chemotherapy was not statistically significantly associated with OS (hazard ratio (HR) = 1.19 [95% confidence interval: 0.89-1.59], P = 0.25; Supplementary Table 1) or RFS (HR = 1.15 [0.86-1.54], P = 0.34; Supplementary Table 2) in the older studies. These findings are similar to those reported by Rowe and colleagues on 1980 adults with newly diagnosed AML treated on six consecutive ECOG trials conducted in the 1980s and early 1990s [9] . In the ECOG trial analysis, 5-and 10-year DFS and OS was not significantly affected by the need for one cycle or two cycles of induction chemotherapy in any of the six trials, even after multivariable adjustment. Using the same methodology as the prior ECOG analysis (analyzing all patients instead of performing a landmark analysis), we found similar results to the landmark analyses above for both OS (HR = 1.21 [0.91-1.63], P = 0.19) and RFS (HR = 1.14 [0.85-1.53], P = 0.37).
In contrast to the data obtained from the older studies, we found receiving two cycles of induction chemotherapy before CR is documented was associated with worse outcome in the S0106 and S1203 trials. Specifically, in these two trials, CR achievement only upon reinduction chemotherapy was statistically significantly associated with worse OS (HR = 1.82 [1.24-2.66], P = 0.002; Supplementary Table 3) or RFS (HR = 1.90 [1.34-2.70], P < 0.001; Supplementary Table 4 ). Fitting a model with an interaction between time-period and reinduction, that interaction was significant (for OS: P = 0.046; for RFS: P = 0.016). Kaplan-Meier estimates of OS and RFS stratified by older vs. newer studies summarize these results graphically (Fig. 1c, d ).
These findings indicate adults with newly diagnosed AML treated on more recent cooperative group trials who achieve remissions early, i.e., with the first cycle of 7+3 chemotherapy, have better survival outlooks than those who need two cycles of chemotherapy to enter a CR, even after adjustment for other risk factors. These data are reminiscent of those obtained from trials of doubleinduction chemotherapy regimens [7, 8] . Why the relationship between time-of-remission achievement and outcome with 7+3 therapy is not seen in older studies is unclear. Possibilities may include the change in anthracycline dose over time (i.e., chemotherapy resistance may be more apparent after the first cycle of chemotherapy with more intense regimens), selection of patients who receive on-study reinduction therapy, and changes in frequency/ routine of transplantation, among others.
Finally, having found evidence that early achievement of morphologic CR was associated with survival with 7+3 chemotherapy, we examined whether data from MRD tests provide additional prognostic information in such patients. For S0106, we previously reported patients in remission without flow cytometric evidence of MRD after completion of induction chemotherapy (either 1 or 2 courses of 7+3) had better outcomes than patients who achieved CR with up to two courses of chemotherapy but had a positive MRD test [15] . Here, we limited these analyses to patients who achieved a morphologic CR with the first cycle of 7+3 and had data from MRD testing available (n = 70). Acknowledging limited power in these analyses because of a relatively small sample size, we found having a negative MRD test (n = 55) after cycle 1 was associated with statistically significantly better OS (P = 0.049) and a trend toward better RFS (P = 0.098) compared to having a positive MRD test after cycle 1 (n = 15; Fig. 1e, f) . Patients who tested negative for MRD after the first cycle of 7+3 also had significantly better RFS (p = 0.02) and a statistically nonsignificant trend (p = 0.11) toward better OS than those who achieved a MRD test-negative CR only after two therapy cycles (Supplementary Figure 1) . Together, our findings not only highlight the prognostic significance of achieving a remission early, but also support the value of "MRD neg CR" as recently proposed by the European LeukemiaNet [2] as new response entity.
